Scarica l'app Stockscreener
2.26
0.89%
0.02
Precedente Chiudi:
$2.24
Aprire:
$2.26
Volume 24 ore:
379
Relative Volume:
0.00
Capitalizzazione di mercato:
$18.06M
Reddito:
$2.90M
Utile/perdita netta:
$87.91M
Rapporto P/E:
0.1448
EPS:
15.6103
Flusso di cassa netto:
$-26.93M
1 W Prestazione:
+3.70%
1M Prestazione:
+3.23%
6M Prestazione:
+32.54%
1 anno Prestazione:
-51.83%
Intervallo 1D:
$2.26
$2.26
Intervallo di 1 settimana:
$2.16
$2.59
Portata 52W:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Nome
Traws Pharma Inc
Settore
Industria
Telefono
267-759-3680
Indirizzo
12 PENNS TRAIL, NEWTOWN
Confronta TRAW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.26 | 18.62M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.04 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.52 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
856.05 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.84 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
195.56 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-18 | Iniziato | Guggenheim | Buy |
| 2018-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-17 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-09 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-27 | Iniziato | Laidlaw | Buy |
| 2015-07-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Traws Pharma Inc Borsa (TRAW) Ultime notizie
Published on: 2025-12-12 06:22:07 - moha.gov.vn
Traws Pharma (TRAW) – Analysts’ Recent Ratings Changes - Defense World
Traws Pharma (NASDAQ:TRAW) Upgraded at Zacks Research - Defense World
0T20 Forecast — Price Target — Prediction for 2026 - TradingView
HC Wainwright Estimates Traws Pharma FY2025 Earnings - Defense World
Traws Pharma (NASDAQ:TRAW) Cut to “Sell” at Wall Street Zen - Defense World
HC Wainwright Estimates Traws Pharma Q4 Earnings - Defense World
HC Wainwright Begins Coverage on Traws Pharma (NASDAQ:TRAW) - Defense World
Can Traws Pharma Inc. (0T20) stock sustain institutional flowsTrade Risk Assessment & Consistent Growth Equity Picks - Newser
What earnings margins imply for Traws Pharma Inc. (0T20) stock2025 Pullback Review & Scalable Portfolio Growth Methods - Newser
Is Traws Pharma Inc. stock trading near support levelsTrade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
How Traws Pharma Inc. (0T20) stock behaves under inflation pressureJuly 2025 Outlook & Precise Trade Entry Recommendations - Newser
Will Traws Pharma Inc. (0T20) stock benefit from sector leadership2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Why ETFs are accumulating Traws Pharma Inc. (0T20) stockQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Is Traws Pharma Inc. (0T20) stock positioned for secular growthWeekly Loss Report & Weekly High Return Stock Forecasts - Newser
Is Traws Pharma Inc. (0T20) stock prepared for digital transition2025 Market WrapUp & Stepwise Trade Signal Guides - Newser
HC Wainwright & Co. Initiates Coverage of Traws Pharma (TRAW) with Buy Recommendation - Nasdaq
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Traws Pharma (TRAW) Receives Buy Rating from HC Wainwright & Co. - GuruFocus
Is Traws Pharma Inc. stock a safe buy before earnings2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Will Traws Pharma Inc. (0T20) stock recover faster than industry - Newser
Traws Pharma (TRAW) Stock Analysis Report | Financials & Insights - Benzinga
Traws Pharma shareholders approve incentive plan changes and elect directors - Investing.com Nigeria
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir - MSN
[Form 4] Traws Pharma, Inc. Insider Trading Activity - Stock Titan
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics - MSN
Is Traws Pharma Inc. stock a defensive play in 2025Rate Cut & Consistent Return Strategy Ideas - newser.com
Is Traws Pharma Inc. (0T20) stock testing key supportCEO Change & Safe Capital Investment Plans - newser.com
Why Traws Pharma Inc. (0T20) stock could be next leaderMarket Activity Summary & Fast Moving Market Watchlists - newser.com
How Traws Pharma Inc. stock reacts to inflationary pressuresLong Setup & Consistent Growth Stock Picks - newser.com
Is Traws Pharma Inc. stock a contrarian buyCEO Change & Consistent Profit Trade Alerts - newser.com
Is a relief rally coming for Traws Pharma Inc. holdersRate Hike & Safe Capital Growth Trade Ideas - newser.com
Traws Pharma, Inc. (TRAW) stock price, news, quote and history - Yahoo Finance UK
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances - MyChesCo
How Traws Pharma Inc. (0T20) stock trades pre earningsWeekly Gains Summary & Long-Term Capital Growth Ideas - newser.com
Traws Pharma Inc Azioni (TRAW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):